Alvin Shih joined Catamaran as President and CEO in February 2021. He is an experienced physician and biopharma executive with a track record of building and leading companies that develop therapeutics addressing significant unmet medical needs. Most recently, Alvin was CEO of Disarm Therapeutics, a private neuroscience company that was acquired by Eli Lilly in 2020. Prior to Disarm, Alvin was CEO of Enzyvant Therapeutics, a company developing cell/tissue-based regenerative medicines for rare diseases. He previously held senior leadership roles at Retrophin and Pfizer, where he was the Chief Operating Officer of the Pfizer Rare Disease Research Unit. Alvin began his career as a strategy consultant at McKinsey & Co. and LEK Consulting. He holds an MD from the University of Alabama, an MBA from the Kellogg School of Management, and a BA from Vanderbilt University. Alvin completed his residency training in internal medicine at the Massachusetts General Hospital.
